Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

Weitz, 1990, Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors, J Clin Invest, 86, 385, 10.1172/JCI114723 Galvani, 1994, Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase, J Am CollCardiol, 24, 1445, 10.1016/0735-1097(94)90138-4 Granger, 1998, Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-1 Trial, J Am Coll Cardiol, 31, 497, 10.1016/S0735-1097(97)00539-1 Kong, 1999, Clinical outcomes of bivalirudin for ischemic heart disease, Circulation, 100, 2049, 10.1161/01.CIR.100.20.2049 Chesebro, 1987, Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge, Circulation, 76, 142, 10.1161/01.CIR.76.1.142 White, 1997, Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO), Circulation, 96, 2155, 10.1161/01.CIR.96.7.2155 White, 1998, Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) Trial, Am J Cardiol, 82, 57P, 10.1016/S0002-9149(98)00663-8 Granger, 1996, Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I Trial, Circulation, 93, 870, 10.1161/01.CIR.93.5.870 Gore, 1995, Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I Trial, Circulation, 92, 2811, 10.1161/01.CIR.92.10.2811 1993, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction, N Engl J Med, 329, 673, 10.1056/NEJM199309023291001 Hosmer, 2000 Lee, 1995, Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients, Circulation, 91, 1659, 10.1161/01.CIR.91.6.1659 Califf, 1997, Selection of thrombolytic therapy for individual patients: development of a clinical model, Am Heart J, 133, 630, 10.1016/S0002-8703(97)70164-9 Morrow, 2000, TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial substudy, Circulation, 102, 2031, 10.1161/01.CIR.102.17.2031 Berkowitz, 1997, Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction, Circulation, 95, 2508, 10.1161/01.CIR.95.11.2508 2001, Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction, Lancet, 358, 605, 10.1016/S0140-6736(01)05775-0 2001, Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial, Lancet, 357, 1905, 10.1016/S0140-6736(00)05059-5 1997, A comparison of reteplase with alteplase for acute myocardial infarction, N Engl J Med, 337, 1118, 10.1056/NEJM199710163371603 1999, Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial, Lancet, 354, 716, 10.1016/S0140-6736(99)07403-6 1995, Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence, Lancet, 346, 329, 10.1016/S0140-6736(95)92224-5 White, 1998, Thrombolytic therapy and equivalence trials, J Am Coll Cardiol, 31, 494 van Domburg, 2001, Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarction, Neth Heart J, 9, 166 Hudson, 2001, Circulation, 104, 1229, 10.1161/hc3601.095717 JA Bittl, BR Chaitman, F Feit, W Kimball, EJ Topol, on behalf of the Bivalirudin Angioplasty Study Investigators. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final reanalysis of the Bivalirudin Angioplasty Study. Am Heart J (in press). 2000, Intravenous NPA for the treatment of infarcting myocardium early: In TIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction, Eur Heart J, 21, 2005, 10.1053/euhj.2000.2498 1993, The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction, N Engl J Med, 329, 1615, 10.1056/NEJM199311253292204 Collins, 1997, Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction, N Engl J Med, 336, 847, 10.1056/NEJM199703203361207 Antman, 1999, Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial, Circulation, 99, 2720, 10.1161/01.CIR.99.21.2720 Ronner, 2000, Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction: a phase II dose escalation, randomized, double-blind study, Eur Heart J, 21, 1530, 10.1053/euhj.1999.2035 ML Simoons, M Krzeminska-Pakula, A Alonso, et al. for the AMI-SK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Eur Heart J (in press).